SCHEMBL5535630

SCHEMBL5535630

[CH2]C(=O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
KDM4E B2RXH2 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
GAA P10253 2/20 0.55
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 2/20 0.53
TSHR P16473 1/20 0.51
LMNA P02545 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29128632 0.86 MEN1 (0.59) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL5540154 0.85 POLB (0.43) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29958946 0.82 GRIN2D (0.60) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL1008398 0.82 POLB (0.63) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL3938038 0.82 POLB (0.58) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL2092532 0.82 POLB (0.58) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL167598 0.82 GRIN2D (0.60) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL6475387 0.82 TAS2R14 (0.56) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL28641153 0.82 ALDH1A1 (0.64) MEN1KMT2AKDM4ESMN1; SMN2GAA
SCHEMBL5142574 0.81 POLB (0.76) POLBMEN1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.